Vaxcyte (PCVX) Retained Earnings (2019 - 2026)

Vaxcyte (PCVX) has reported Retained Earnings for 8 consecutive years, with -$2.5 billion the latest figure, recorded in Q1 2026.

• In Q1 2026, Retained Earnings fell 61.9% year-over-year to -$2.5 billion; the TTM figure through Mar 2026 stood at -$2.5 billion (down 61.9% YoY), while the FY2025 annual figure was -$2.2 billion, down 55540.25% from the prior year.
• Retained Earnings declined to -$2.5 billion in Q1 2026 per PCVX's latest filing, from -$2.2 billion in the prior quarter.
• Across five years, Retained Earnings topped out at $2.9 million in Q1 2024 and bottomed at -$2.5 billion in Q1 2026.
• Historically, Retained Earnings has averaged -$579.9 million across 5 years, with a median of -$3.9 million in 2024.
• Annual changes were most pronounced in 2023 — Retained Earnings slumped 255964.27% — and 2025, when it jumped 515.83%.
• Vaxcyte's Retained Earnings stood at -$361000.0 in 2022, then plunged by 255964.27% to -$924.4 million in 2023, then jumped by 99.58% to -$3.9 million in 2024, then sank by 55540.25% to -$2.2 billion in 2025, then decreased by 14.88% to -$2.5 billion in 2026.
• Business Quant data shows PCVX's Retained Earnings at -$2.5 billion in Q1 2026, -$2.2 billion in Q4 2025, and $856000.0 in Q3 2025.